Departamento de Biología Celular, CINVESTAV-IPN, Av. IPN 2508, C.P. 07360 Ciudad de México, Mexico.
Departamento de Toxicología, CINVESTAV-IPN, Av. IPN 2508, C.P. 07360 Ciudad de México, Mexico.
Biochem Pharmacol. 2019 Oct;168:429-437. doi: 10.1016/j.bcp.2019.08.002. Epub 2019 Aug 9.
Parkin (PRKN) is a ubiquitin E3 ligase that catalyzes the ubiquitination of several proteins. Mutations in the human Parkin gene, PRKN, leads to degeneration of dopaminergic (DA) neurons, resulting in autosomal recessive early-onset parkinsonism and the loss of PRKN function is linked to sporadic Parkinson's disease (PD). Additionally, several in vitro studies have shown that overexpression of exogenous PRKN protects against the neurotoxic effects induced by a wide range of cellular stressors, emphasizing the need to study the mechanism(s) governing PRKN expression and induction. Here, Prkn was identified as a novel target gene of the aryl hydrocarbon receptor (AhR), a ligand-activated transcription factor and member of the bHLH/PAS (basic helix-loop-helix/Per-Arnt-Sim) superfamily. AhR binds and transactivates the Prkn gene promoter. We also demonstrated that AhR is expressed in DA neurons and that its activation upregulates Prkn mRNA and protein levels in the mouse ventral midbrain. Additionally, the AhR-dependent increase in PRKN levels is associated with a decrease in the protein levels of its target substrate, α-synuclein, in an AhR-dependent manner, because this effect is not observed in Ahr-null mice. These results suggest that treatments designed to induce PRKN expression through the use of nontoxic AhR agonist ligands may be novel strategies to prevent and delay PD.
Parkin(PRKN)是一种泛素 E3 连接酶,能够催化几种蛋白质的泛素化。人类 Parkin 基因(PRKN)的突变导致多巴胺能(DA)神经元的退化,导致常染色体隐性早发性帕金森病,而 PRKN 功能的丧失与散发性帕金森病(PD)有关。此外,几项体外研究表明,外源性 PRKN 的过表达可以防止多种细胞应激诱导的神经毒性作用,这强调了研究调控 PRKN 表达和诱导的机制的必要性。在这里,Prkn 被鉴定为芳香烃受体(AhR)的一个新的靶基因,AhR 是一种配体激活的转录因子,属于 bHLH/PAS(碱性螺旋-环-螺旋/Per-Arnt-Sim)超家族。AhR 结合并反式激活 Prkn 基因启动子。我们还证明,AhR 在 DA 神经元中表达,其激活以 AhR 依赖的方式上调小鼠腹侧中脑中 Prkn mRNA 和蛋白质水平。此外,PRKN 水平的 AhR 依赖性增加与靶底物α-突触核蛋白的蛋白质水平降低有关,这是因为在 Ahr 缺失小鼠中观察不到这种效应。这些结果表明,通过使用非毒性 AhR 激动剂配体诱导 PRKN 表达的治疗方法可能是预防和延迟 PD 的新策略。